Brilliant another day closer 2 that amazing update26 Feb 2025 13:49
This is what I'm focusing on very clear and transparent and very very positive step for Hemogenyx.. Take a minute and just understand how far HEMOGENYX have come.
First-in-Human Treatment with HG-CT-1 for Relapsed or Refractory Acute Myeloid Leukemia
Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce the administration of its first-in-human dose of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a major milestone in the Company's clinical development program, demonstrating progress toward delivering a potentially life-saving treatment for AML patients with limited therapeutic options.
Further updates on the clinical trial will be provided in due course.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are thrilled to take this critical step in advancing the development of HG-CT-1. This milestone not only validates our years of research and development, but also brings us closer to providing a transformative treatment for patients suffering from relapsed or refractory AML...